Tianqing Chu

5PUBLICATIONS
6CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 29, 2026
TRMT1-mediated tRNA m22G modification drives Osimertinib resistance via the ATXN3/USP25 axis in lung adenocarcinoma.

|May 15, 2026
PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.

|Mar 26, 2025
Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study.

Runbo Zhong, Tianqing Chu, Liwen Xiong

|Feb 18, 2020
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.

Huiping Qiang, Qing Chang, Jianlin Xu

|Mar 23, 2019
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.

Qing Chang, Yanwei Zhang, Jianlin Xu

Pageof 1

Frequent Collaborators

2 joint publications

Runbo Zhong

1 joint publications

Qing Chang

1 joint publications

Xueyan Zhang

1 joint publications

Hongping Jin